COVID Vaccine Sales Are Declining. But Here's How They're Still Driving Growth at Moderna.
Right now, (NASDAQ: MRNA) generates pretty much all of its revenue from one product: its coronavirus vaccine. That was fine in early pandemic days, as strong vaccine demand equaled billions of dollars in sales every quarter.
But as we move toward a post-pandemic world, and as vaccine sales slip, investors have shied away from the biotech player. As a result, the shares are heading for a 39% decline this year.
Before you turn your back on Moderna stock, though, there's something you should know: Vaccine sales still are driving growth at this innovative biotech. Let's find out how -- and if this makes the stock a buy.
Source Fool.com
Moderna Inc. Aktie
79,37 €
0,74 %
Und Moderna Inc. steht derzeit mit 21 Buy-Einschätzungen und 2 Sell-Einschätzungen bei unserer Community gut im Kurs.
Eine deutliche Steigerung um mehr als 50% ist für Moderna Inc. mit einem Kursziel von 129 € gegenüber 79.37 € zu erwarten.
